menu
    • menu
    [{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio \/ Omega Funds"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"VQ-201","moa":"C5aR1","graph1":"Immunology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":1.0600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.0600000000000001,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio \/ Biogen"}]

    Find Clinical Drug Pipeline Developments & Deals by Vanqua Bio

    Menu

    Vanqua Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VQ-201

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Biogen

                            Deal Size : $1,060.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio for Immunology Portfolio Expansion

                            Details : Through the licensing deal for VQ-201, targeting C5aR1, the agreement aims to advance treatment options for inflammatory disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $70.0 million

                            October 24, 2025

                            Lead Product(s) : VQ-201

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Biogen

                            Deal Size : $1,060.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vanqua Reports Positive Interim Results For VQ-101 in Parkinson’s Disorder

                            Details : VQ-101 is an orally administered brain-penetrant allosteric activator of the lysosomal enzyme glucocerebrosidase. It is being evaluated for the treatment of GBA1 mutated Parkinson’s Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vanqua Bio Doses First Patient in Phase 1 Trial Of VQ-101 for GBA-Parkinson's Disease

                            Details : VQ-101 is an orally administered glucocerebrosidase activator being evaluated for GBA1-mutated Parkinson's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2024

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vanqua Presents Preclinical Data on VQ-101, a GCase Activator for GBA-Parkinson's

                            Details : VQ-101 is a novel small molecule allosteric activator of glucocerebrosidase (GCase), which is being evaluated for the treatment of GBA-Parkinson’s Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 27, 2024

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Dev...

                            Details : VQ-101 is a GCase enzyme activator, small molecule drug candidate, which is currently being evaluated for the treatment of patients with Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2023

                            Lead Product(s) : VQ-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Vanqua Bio

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Omega Funds

                            Deal Size : $85.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Vanqua Bio Launches with $85 Million Series B Financing and A Mission to Vanquish Neurodegenerative Diseases

                            Details : Proceeds from the financing will be used to accelerate the development of Vanqua Bio’s programs in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Omega Funds

                            Deal Size : $85.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth